Vaccitech $110.5 million IPO
Davis Polk advised the representatives of the several underwriters in connection with Vaccitech plc’s $110.5 million U.S. initial public offering of 6,500,000 American depositary shares representing 6,500,000 ordinary shares. The ADSs are listed on the Nasdaq Global Market under the symbol “VACC.”
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation.
The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Marcel Fausten and associates Joze Vranicar and Dennis Chu. Partner Simon Witty and associate Aya Aboulatta provided English law advice. The intellectual property and technology transactions team included partner David R. Bauer and associate Hilary Smith Partner Jonathan Cooklin and counsel Kiara L. Rankin provided U.S. and English tax advice. Members of the Davis Polk team are based in the New York and London offices.